Trials / Completed
CompletedNCT01273376
Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study of RX-10100 in Subjects With Major Depressive Disorder.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 314 (actual)
- Sponsor
- Rexahn Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether RX-10100 are effective in the treatment of Major Depressive Disorder (MDD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RX-10100 | Extended-release tablet, taken twice daily for 8 weeks |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2011-09-01
- Completion
- 2011-10-01
- First posted
- 2011-01-10
- Last updated
- 2013-11-19
Locations
44 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01273376. Inclusion in this directory is not an endorsement.